The first annual meeting took place at the same time, with papers in French, German and English being presented -it was not until 1970-1971 that English was adopted as the single language of the EASD.
The list of authors of these first presentations makes interesting reading. They include EF Pfeiffer, WJH Butterfield, JP Felber, W Malaisse,
LG Heding, R Korec, PH Sönksen, ER Froesch, J Pirart, W Creutzfeldt, A Czyzyk, Z Skrabalo, R Oesterby and H Keen. Back then there were only 48 submissions, a far cry from the 2,300+ abstracts now received each year.
Today, the EASD has moved into an era of technology and mass internet communication. The development of the EASD Virtual Meeting gives all interested parties the opportunity to view world-class presentations on the newest advances in diabetes research and treatments. They can been viewed for free on the internet and through SmartPhone Apps.
The mission of the EASD is to promote excellence in diabetes care through research and education -a mission we strive to achieve with our free access to information and postgraduate courses worldwide. have awarded, since 2007, approximately 5,000 grants, supported more than 10,000 doctoral students and more than 5,000 postdocs. It can also add five Nobel Prizes and three Fields Medallists to its accolades. 4 However, Europe also faces unique problems -the main one being the lack of research co-ordination at EU, national and regional levels. The research community is dispersed among numerous nations. Therefore, it faces not only geographical challenges but also communication difficulties. One of the major goals of the Biomedical Alliance is to encourage collaborative, multidisciplinary partnerships across borders in order to accelerate translation of discoveries into applications that impact healthcare delivery, particularly in times of economic austerity. It is only by addressing these concerns that high-quality research outcomes can reach European citizens as quickly as possible. Failure to achieve this would lead to Europe falling even further behind its global competitors.
The costs may seem astronomical, but it is worth noting that, with an estimated 371 million diabetes patients worldwide, US$470 billion was spent on diabetes care. However, the number which is of most relevance, and truly shocking is that, in 2012, 4.8 million lives were lost to this disease. 5 Great strides are being made thanks to bodies such as the EFSD, which, thanks in part to third-party support, subsidises researchers and helps the wider medical community achieve new levels of knowledge and strive for excellence in healthcare and disease management. Over the course of its history, the EASD and the EFSD grants and fellowships have had a major impact on the quality of medical care for diabetes patients.
In our area of interest, each new study and each new clinical trial takes us one step closer to the ultimate goal of finding a cure for diabetes.
For further information on EASD or EFSD, please visit www.easd.org. n
